Tci Wealth Advisors, Inc. Fate Therapeutics Inc Transaction History

Tci Wealth Advisors, Inc.

$1.12 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	BUY	$9.86 - $23.83 $2,218 - $5,361	225 Added 60.98%	594 $5,000
Q3 2022 Nov 08, 2022	BUY	$21.04 - $36.06 $1,830 - $3,137	87 Added 30.85%	369 $8,000
Q2 2022 Jul 19, 2022	BUY	$17.78 - $42.39 $2,346 - $5,595	132 Added 88.0%	282 $7,000
Q1 2022 Apr 29, 2022	SELL	$29.67 - $60.28 $7,565 - $15,371	-255 Reduced 62.96%	150 $6,000
Q4 2021 Jan 24, 2022	BUY	$47.84 - $64.34 $2,918 - $3,924	61 Added 17.73%	405 $24,000
Q3 2021 Oct 29, 2021	BUY	$59.27 - $95.73 $5,097 - $8,232	86 Added 33.33%	344 $20,000
Q2 2021 Aug 02, 2021	SELL	$67.25 - $92.52 $21,183 - $29,143	-315 Reduced 54.97%	258 $22,000
Q1 2021 Apr 29, 2021	BUY	$72.16 - $117.4 $5,267 - $8,570	73 Added 14.6%	573 $47,000
Q4 2020 Jan 21, 2021	SELL	$38.09 - $100.95 $11,427 - $30,285	-300 Reduced 37.5%	500 $45,000
Q3 2020 Oct 20, 2020	SELL	$30.41 - $40.5 $760 - $1,012	-25 Reduced 3.03%	800 $32,000
Q1 2020 Apr 14, 2020	SELL	$17.28 - $31.88 $1,728 - $3,188	-100 Reduced 10.81%	825 $18,000
Q4 2019 Jan 27, 2020	SELL	$13.39 - $20.73 $5,356 - $8,292	-400 Reduced 30.19%	925 $18,000
Q3 2019 Oct 17, 2019	SELL	$15.47 - $22.5 $1,547 - $2,250	-100 Reduced 7.02%	1,325 $21,000
Q1 2019 Apr 11, 2019	SELL	$13.15 - $18.71 $3,945 - $5,613	-300 Reduced 17.39%	1,425 $25,000
Q4 2018 Jan 17, 2019	BUY	$11.48 - $16.98 $1,148 - $1,698	100 Added 6.15%	1,725 $22,000
Q3 2018 Nov 02, 2018	SELL	$8.75 - $16.29 $875 - $1,629	-100 Reduced 5.8%	1,625 $26,000
Q2 2018 Jul 27, 2018	BUY	$9.16 - $13.48 $916 - $1,348	100 Added 6.15%	1,725 $20,000
Q1 2018 Apr 30, 2018	BUY	$6.3 - $13.77 $630 - $1,377	100 Added 6.56%	1,625 $16,000
Q4 2017 Feb 01, 2018	SELL	$3.94 - $6.64 $295 - $498	-75 Reduced 4.69%	1,525 $9,000
Q3 2017 Oct 24, 2017	BUY	$2.6 - $4.31 $2,080 - $3,447	800 Added 100.0%	1,600 $6,000
Q2 2017 Aug 10, 2017	BUY	N/A	800	800 $3,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

Redmile Group, LLC San Francisco, CA

13.2M
Shares

$21.9 Million
3.01% of portfolio
Vanguard Group Inc Valley Forge, PA

10.4M
Shares

$17.3 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$16.8 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

5.57M
Shares

$9.25 Million
0.72% of portfolio
State Street Corp Boston, MA

5.25M
Shares

$8.72 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.

Account